1. Introduction {#sec1-marinedrugs-16-00434}
===============

*Xylocarpus granatum*, a true mangrove plant, belongs to the family Meliaceae, of which the main secondary metabolites are limonoids \[[@B1-marinedrugs-16-00434],[@B2-marinedrugs-16-00434]\]. Krishnolide A, a khayanolide-type of limonoid isolated from the Indian mangrove, *Xylocarpus moluccensis*, showed moderate antiviral activity against human immunodeficiency virus 1 (HIV-1) with an IC~50~ value of 17.45 ± 1.65 μM and a CC~50~ value of 78.45 ± 1.69 μM, respectively \[[@B3-marinedrugs-16-00434]\]. Three other khayanolide-type of limonoids obtained from the Thai *Xylocarpus moluccensis*, *viz.* thaixylomolins I, K, and M, exhibited moderate antiviral activity against influenza A virus (IAV). The most potent one is thaixylomolin I with an IC~50~ value of 77.1 ± 8.7 μM \[[@B4-marinedrugs-16-00434]\].

Limonoids containing a C~1~--*O*--C~29~ moiety are a small group of natural products. To date, only 34 compounds of this group, including xyloccensin L, xylogranatin E, granaxylocarpin C, granatumins L--T and V--Y, sundarbanxylogranins C--E, krishnagranatins A--F, thaixylogranin D, godavarins D--G and K, moluccensin W, and erythrocarpines D--E, have been reported from mangrove plants of the genus *Xylocarpus* and the land plant *Chisocheton erythrocarpus* \[[@B5-marinedrugs-16-00434],[@B6-marinedrugs-16-00434],[@B7-marinedrugs-16-00434],[@B8-marinedrugs-16-00434],[@B9-marinedrugs-16-00434],[@B10-marinedrugs-16-00434],[@B11-marinedrugs-16-00434],[@B12-marinedrugs-16-00434],[@B13-marinedrugs-16-00434]\]. It is worth noting that 28 compounds of this group were obtained from *X. granatum* \[[@B5-marinedrugs-16-00434],[@B6-marinedrugs-16-00434],[@B7-marinedrugs-16-00434],[@B8-marinedrugs-16-00434],[@B9-marinedrugs-16-00434],[@B10-marinedrugs-16-00434],[@B11-marinedrugs-16-00434]\]. However, only one limonoid containing a C~1~--*O*--C~29~ moiety, i.e., thaixylogranin D, was identified from the Thai *X. granatum* \[[@B11-marinedrugs-16-00434]\]. To search for new antiviral natural compounds from mangrove plants, seeds of the Thai *X. granatum*, collected in the mangrove swamp of Trang Province, were investigated to afford five new limonoids containing a C~1~--*O*--C~29~ moiety, named thaigranatins A--E (**1**--**5**), along with the known one, granatumin L (**6**) ([Figure 1](#marinedrugs-16-00434-f001){ref-type="fig"}), which exhibited antiviral activity against HIV-1. To find promising antiviral drug leads, structural modification was applied to granatumin L (**6**). Herein, we report the isolation and structural elucidation of thaigranatins A--E (**1**--**5**), the structural modification of granatumin L (**6**), and antiviral activities of the modified derivatives of **6** against HIV-1 and IAV.

2. Results and Discussion {#sec2-marinedrugs-16-00434}
=========================

2.1. Structure Identification of Natural Limonoids ***1**--**5*** {#sec2dot1-marinedrugs-16-00434}
-----------------------------------------------------------------

Compound 1 was obtained as colorless crystals. Its molecular formula C~32~H~40~O~10~, indicating 13 degrees of unsaturation, was established by the positive HR-ESIMS ion peak at *m*/*z* 607.2509 (calcd. for \[M + Na\]^+^ 607.2514). According to the ^1^H and ^13^C NMR spectroscopic data ([Table 1](#marinedrugs-16-00434-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00434-t002){ref-type="table"}), 7 degrees of unsaturation were due to 3 carbonyl groups and 4 carbon-carbon double bonds; thus, the molecule was hexacyclic. The ^13^C NMR spectroscopic data and DEPT experiments indicated the presence of 6 methyl groups (a methoxy group, a methyl group linked to a secondary carbon and 4 methyl groups linked to tertiary carbons), 4 methylene groups, 12 methine groups (including 5 olefinic), and 10 quaternary carbons (including 3 carbonyl groups) in **1**.

The NMR spectroscopic data of **1** ([Table 1](#marinedrugs-16-00434-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00434-t002){ref-type="table"}) and its 2D correlations (^1^H--^1^H COSY, HSQC, and HMBC) indicated the presence of a methoxycarbonyl moiety \[*δ*~H~ 3.76 (s, H~3~-OMe); *δ*~C~ 53.2 (C-OMe), 176.1 (C-7)\], a tigloyl group \[*δ*~H~ 6.83 (q, *J* = 7.2 Hz), 1.67 (d, *J* = 7.2 Hz), 1.79 s; *δ*~C~ 167.2 qC, 127.8 qC, 138.7 CH, 14.6 CH~3~, 11.7 CH~3~\], an oxygenated methylene moiety \[*δ*~H~ 4.60 (d, *J* = 8.8 Hz, H*~pro-S~*-29), 3.45 (d, *J* = 8.8 Hz, H*~pro-R~*-29); *δ*~C~ 70.1 (C-29)\], and a typical *β*-furyl ring \[*δ*~H~ 7.50 (br s, H-21), 6.39 (br d, *J* = 1.2 Hz, H-22), 7.44 (t, *J* = 1.6 Hz, H-23); *δ*~C~ 121.5 (C-20, qC), 140.3 (C-21, CH), 109.3 (C-22, CH), 143.1 (C-23, CH)\]. A *δ*-lactone ring (C-13, C-14, C-15, C-16, and C-17), characterized by NMR spectroscopic data \[*δ*~H~ 2.31 (br s, H-14), 2.82 (m, H~2~-15); *δ*~C~ 36.7 (C-13, qC), 44.8 (C-14, CH), 29.6 (C-15, CH~2~), 169.3 (C-16, qC), and 76.6 (C-17, CH)\], was corroborated by HMBC correlations between H~2~-15/C-13, H~2~-15/C-14, H~2~-15/C-16, H-17/C-13, H~3~-18/C-13, and H~3~-18/C-14 ([Figure 2](#marinedrugs-16-00434-f002){ref-type="fig"}a). An olefinic methine group \[*δ*~H~ 5.28 (d, *J* = 6.8 Hz); *δ*~C~ 120.2\], exhibiting a ^1^H--^1^H COSY correlation to H-2 and HMBC correlations to C-9 and C-14, was attributed to CH-30.

The NMR spectroscopic data of **1** ([Table 1](#marinedrugs-16-00434-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00434-t002){ref-type="table"}) resembled those of granatumin L (**6**) \[[@B8-marinedrugs-16-00434]\], except for the presence of an additional 6-OH group in **1**, being corroborated by the downshifted C-6 signal (*δ*~C~ 72.5 CH in **1**; whereas *δ*~C~ 31.9 CH~2~ in granatumin L). ^1^H--^1^H COSY correlation between H-5/H-6 and HMBC correlations between H-6/C-5 and H-6/C-7 ([Figure 2](#marinedrugs-16-00434-f002){ref-type="fig"}a) further confirmed the above result.

The relative configuration of **1**, except for the chirality of C-6, was established to be the same as that of granatumin L (**6**) based on NOE interactions. Those from H-3 to H*~pro-R~*-29 \[*δ*~H~ 3.45 (d, *J* = 8.8 Hz)\], but not from H-3 to H-5, established the *α*-oriented H-3 and the corresponding 3*β*-*O*-tigloyl group. NOE interactions between H~3~-18/H-14, H-9/H~3~-19, and H-3/H-2 indicated their mutual *cis* relationship and the *α*-oriented H-14, H-9, and H-2. Similarly, those between H-5/H-11*β*, H-5/H-17, and H-17/H-12*β* indicated the *β*-orientation of H-5 and H-17 ([Figure 2](#marinedrugs-16-00434-f002){ref-type="fig"}b).

After considerable effort, suitable crystals of **1** were obtained in methanol/chloroform (4:1) at room temperature. Thus, the absolute configuration of **1** was unequivocally established as 1*R*,2*S*,3*R*,4*S*,5*S*,6*R*,9*S*,10*R*,13*R*,14*S*,17*R* ([Figure 3](#marinedrugs-16-00434-f003){ref-type="fig"}, CCDC-1871152) by single-crystal X-ray diffraction analysis, conducted with CuKα radiation \[Flack parameter of 0.02(3)\]. Thus, the structure of **1**, thaigranatin A, was assigned as depicted.

Compound **2**, an amorphous powder, had the molecular formula C~30~H~38~O~9~ as established by the positive HR-ESIMS ion peak at *m/z* 543.2593 (calcd. for \[M + H\]^+^ 543.2589). The ^1^H and ^13^C NMR spectroscopic data of **2** ([Table 1](#marinedrugs-16-00434-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00434-t002){ref-type="table"}) were similar to those of **1**, except for the absence of the 6-OH group and the replacement of the 3-*O*-tigloyl group in **1** by a 3-*O*-propionyl moiety \[*δ*~H~ 2.37 (m, 2H), 1.09 (t, *J* = 7.2 Hz, 3H); *δ*~C~ 174.5 qC, 27.1 CH~2~, 8.7 CH~3~\]. The HMBC correlation from H-3 \[*δ*~H~ = 4.84 (d, *J* = 10.0 Hz)\] to the carbonyl carbon (*δ*~C~ = 174.5 qC) of the propionyl group confirmed its location at C-3. The absence of the 6-OH group in **2** was corroborated by the upshifted CH~2~-6 \[*δ*~H~ 2.35 (m H~2~-6); *δ*~C~ 31.9 qC\] in **2**. ^1^H--^1^H COSY correlations between H~2~-6/H-5 and HMBC correlations from H~2~-6 to C-5 and C-7 confirmed the above result.

The relative configuration of **2** was determined to be the same as that of **1** by NOE interactions between H-17/H-11*β*, H-11*β*/H-5, and H-17/H-5, and those between H~3~-19/H-9, H~3~-19/H*~pro-S~*-29, H-3/H*~pro-R~*-29, H-3/H-2, and H~3~-18/H-14. The absolute configuration of **2**, except for the deficiency of the chiral C-6, was established to be the same as that of **1**, i.e., (1*R*,2*S*,3*R*,4*S*,5*S*,9*S*,10*R*,13*R*,14*S*,17*R*), by the accurate fit of their experimental electronic circular dichroism (ECD) spectra ([Figure 4](#marinedrugs-16-00434-f004){ref-type="fig"}). Thus, the structure of **2**, thaigranatin B, was assigned as depicted.

The molecular formula of **3** was determined to be C~32~H~40~O~10~ by HR-ESIMS ion peak at *m*/*z* 607.2512 (calcd. for \[M + Na\]^+^ 607.2514). The NMR spectroscopic dataof **3** ([Table 1](#marinedrugs-16-00434-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00434-t002){ref-type="table"}) were similar to those of godavarin D \[[@B12-marinedrugs-16-00434]\], the difference being the presence of an additional 30-OH group, which was corroborated by the downshifted C-30 (*δ*~C~ 66.3 CH in **3**, whereas *δ*~C~ 26.3 CH~2~ in godavarin D) and ^1^H--^1^H COSY correlation between H-2/H-30. HMBC correlations from H-30 to C-1, C-2, C-3, C-8, C-9, and C-14 confirmed the above result ([Figure 5](#marinedrugs-16-00434-f005){ref-type="fig"}a).

The relative configuration of **3** was established by NOE interactions ([Figure 5](#marinedrugs-16-00434-f005){ref-type="fig"}b). Those between H-3/H~pro-*R*~-29, H-3/H-2, H~3~-19/H-9, H~3~-18/H-11*α* assigned the *α*-oriented H-2, H-3, H~3~-18, and H~3~-19; whereas those between H-17/H-12*β*, H-12*β*/H-5, and H-17/H-5 established the *β*-oriented H-5 and H-17. The small coupling constant of *J*~2,30~, i.e., 2.4 Hz, revealed the *J*~e,e~ coupling for H-2 and H-30, and thus the corresponding equatorial bond for H-30, i.e., the *β*-oriented H-30, which was further corroborated by NOE interactions between H-30/H-15*α* and H-30/H-15*β* of equal intensity, and no observation of NOE interaction between H-30/H-9. Thus, the structure of **3**, thaigranatin C, was assigned as shown.

The molecular formula of **4** was established as C~32~H~40~O~10~ by the positive HR-ESIMS ion peak at *m*/*z* 585.2694 (calcd. for \[M + H\]^+^ 585.2694). The NMR spectroscopic data of **4** ([Table 1](#marinedrugs-16-00434-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00434-t002){ref-type="table"}) were similar to those of godavarin D \[[@B12-marinedrugs-16-00434]\], except for the presence of an additional 6-OH group, which was corroborated by the downshifted C-6 (*δ*~C~ 73.1 CH in **4**; whereas *δ*~C~ 32.2 CH~2~ in godavarin D) \[[@B12-marinedrugs-16-00434]\]. ^1^H--^1^H COSY correlation between H-6/H-5 and HMBC correlations from H-6 to C-5 and C-7 confirmed the above result.

NOE interactions between H-17/H-12*β* and H-17/H-5 established the *β*-oriented H-5 and H-17. In turn, those between H~3~-18/H-11*α*, H~3~-19/H-9, H-3/H~pro-*R*~-29, assigned the *α*-oriented H~3~-19, H-9, H~3~-18, and H-3. Thus, the structure of **4**, thaigranatin D, was assigned as depicted.

Compound **5** gave the molecular formula C~32~H~40~O~10~ as obtained from the positive HR-ESIMS ion at *m*/*z* 607.2511 \[M + Na\]^+^ (calcd. for C~32~H~40~NaO~10~, 607.2514). The NMR spectroscopic data of **5** ([Table 1](#marinedrugs-16-00434-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00434-t002){ref-type="table"}) resembled those of **3**, except for the replacement of the Δ^8,14^ double bond in **3** by a Δ^8,9^ double bond \[*δ*~C~ 127.1 (C-8, qC), 139.2 (C-9, qC)\]. HMBC correlations between H-15/C-8, H-15/C-9, H-30/C-8, H-30/C-9, and H~3~-19/C-9 confirmed the above deduction.

The relative configuration of **5** was established based on NOE interactions. Those between H-17/H-12*β* and H-5/H-11*β* assigned the *β*-oriented H-17 and H-5. NOE interactions between H~3~-18/H-14, H~3~-18/H-11*α*, and H-3/H~pro-*R*~-29 assigned the *α*-orientation for H-14, H~3~-18, H~3~-19, and H-3. The broad singlet of H-30 revealed the *J*~e,e~ coupling for H-2 and H-30, and thus assigned the corresponding equatorial bond for H-30, i.e., the β-oriented H-30. Thus, the structure of **5**, thaigranatin E, was assigned as depicted.

NMR data are shown in [Table 1](#marinedrugs-16-00434-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00434-t002){ref-type="table"}.

2.2. Structural Modifications of Granatumin L *(**6**)* {#sec2dot2-marinedrugs-16-00434}
-------------------------------------------------------

In our previous bioassay, granatumin L (**6**) showed an inhibitory rate of 67.10 ± 3.04% against HIV-1 at the concentration of 20 μM. Thus, structural modification of the natural compound **6**, particularly the bioequivalent substitution of the C-3 natural substituent, was investigated to find its potent and selective antiviral analogs. To achieve this purpose, 3 different protocols, *viz.* hydrolysis with alkaline KOH, esterification with diazomethane and various organic acids, and oximization with hydroxyamine, were employed ([Scheme 1](#marinedrugs-16-00434-sch001){ref-type="scheme"}).

Compound **7** was obtained by the hydrolysis of **6** with an alkaline KOH. The ester functions at the C-3 and C-7 positions of **7** were hydrolyzed to give a hydroxy group at the C-3 position and a carboxyl group at the C-7 position, respectively, in the yield of 96.8%. Owing to the formation of the stable six-membered ring, the *δ*-lactone function of ring-D was not hydrolyzed. Then, **7** was treated with diazomethane to afford **8** as expected. Afterwards, the hydroxy group at the C-3 position of **8** was oxidized with IBX to give **9** with a carbonyl group at the C-3 position. Fortunately, the hemiacetal function of **8** was retained under the reaction condition.

Alternatively, **7** was first oxidized and then methylated to prepare **9**. An intermediate compound **10** was obtained in the high yield of 98.8%. However, the final yield of **9** was 76.2%, which made this strategy inadvisable. Finally, the hydroxy group at the C-3 position of **8** was esterified with various organic acids to afford a series of compounds **8a**--**8i**. The bioisosteric substitution of the ketone function at the C-3 position of **9** and **10** with different oximes led to the generation of derivatives **9a**--**9b** and **10a**--**10c**, respectively.

2.3. Antiviral Activity Bioassay {#sec2dot3-marinedrugs-16-00434}
--------------------------------

The inhibitory activities of natural limonoid **6** and all the modified derivatives **7**--**10**, **8a**--**8i**, **9a**--**9b**, and **10a**--**10c** against HIV-1 were tested \[[@B14-marinedrugs-16-00434]\]. Efavirenz was used as the positive control. The results were summarized in [Table 3](#marinedrugs-16-00434-t003){ref-type="table"}. The lack of substituent at the C-3 position of **8**, **9**, and **10** combined with the disappearance of their anti-HIV-1 activities indicated that the substituent at the C-3 position is essential for anti-HIV-1 activity of this limonoid skeleton. The oxidation of the hydroxy group at the C-3 position into a carbon-oxygen or carbon-nitrogen double bond did not improve anti-HIV-1 activity. For example, derivatives **9a**--**9b** and **10a**--**10c** containing a C=O or C=N double bond exhibited no activity.

Anti-HIV-1 bioassay ([Table 3](#marinedrugs-16-00434-t003){ref-type="table"}) revealed that the C-3 esterified products, particularly derivatives with a fatty acid ester at the C-3 position, markedly enhanced anti-HIV-1 activity. The derivative **8i** exhibited the highest inhibition rate of 99.95 ± 0.01% at the concentration of 20.0 μM; whereas **8g** showed an inhibition rate of 50.84 ± 6.96% at the same concentration. The IC~50~ values for **8i** and **8g** are 15.98 ± 6.87 and 21.98 ± 4.65 μM, respectively, among which the former is better than that of **6** (19.23 ± 0.12 μM). The results indicated that the introduction of alkyl groups at the C-3 position helped to maintain anti-HIV-1 activity. However, compounds with aromatic substitution at the C-3 position showed decreased activity.

Antiviral activities of all the modified derivatives of **6** against IAV were also evaluated \[[@B14-marinedrugs-16-00434]\]. Ribavirin was used as the positive control. Derivatives **8i** and **8g** exhibited no inhibitory activities against IAV at the concentration of 20.0 μM; whereas **8b**, **8c**, **8d**, and **10b** showed marked anti-IAV activities with IC~50~ values in the range of 14.0--22.8 μM ([Table 4](#marinedrugs-16-00434-t004){ref-type="table"}). The strongest inhibitory activity of **10b** revealed the importance of a C-3--substituted *O*-methyl oxime group.

The above anti-HIV-1 and anti-IAV activities of modified derivatives shed light on the structural optimization of natural limonoid **6**, particularly suitable substituted groups at the C-3 position. In-depth structural modification and structure-activity relationship studies of the limonoid skeleton of **6** will be proceeded by us in the near future.

3. Materials and Methods {#sec3-marinedrugs-16-00434}
========================

3.1. General {#sec3dot1-marinedrugs-16-00434}
------------

Optical rotations were measured on a MCP200 modular circular polarimeter (Anton Paar OptoTec GmbH, Seelze, Germany). UV spectra were obtained on a GENESYS 10S UV--Vis spectrophotometer (Thermo Fisher Scientific, Shanghai, China). NMR spectra were recorded on a Bruker AV-400 spectrometer (Bruker Scientific Technology Co. Ltd., Karlsruhe, Germany) with TMS as the internal standard. HR-ESIMS were measured on a Bruker maXis ESI-QTOF mass spectrometer (Bruker Daltonics, Bremen, Germany). Semi-preparative HPLC was performed on C~18~ reversed-phase silica gel columns (YMC 250 × 10 mm i.d., or 250 × 4.6 mm i.d.) using a Waters 2535 pump equipped with a Waters 2489 UV detector (Waters Corporation, Milford, MA, USA). Silica gel (100--200 mesh) (Qingdao Marine Chemical Industrial Co. Ltd., Qingdao, China) and C~18~ reversed-phase silica gel (ODS-A-HG 12 nm, 50 μm, YMC Co. Ltd., Kyoto, Japan) were used for column chromatography. ECD spectra were measured on a Jasco J-810 spectropolarimeter (JASCO Corporation, Tokyo, Japan) in MeCN.

3.2. Plant Material {#sec3dot2-marinedrugs-16-00434}
-------------------

Seeds of *Xylocarpus granatum* were collected in August 2012 from the Thai mangrove swamps of the Trang Province. Identification of the mangrove was done by one of the authors (J.W.). A voucher sample (No. ThaiXG-02) is maintained in Marine Drugs Research Center, College of Pharmacy, Jinan University.

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-16-00434}
-----------------------------

The air-dried and powdered seeds (9.0 kg) of *Xylocarpus granatum* were extracted 5 times with EtOH (95%, *v*/*v*) at room temperature to afford the resulting extract (1363.6 g). After removal of the solvent under vacuum, the residue was partitioned between water and EtOAc to yield the EtOAc portion (307.7 g). The EtOAc portion (150 g) was chromatographed on a silica gel column (70 × 15 cm i.d.), eluted with a gradient mixture of CHCl~3~/MeOH (100:0 to 5:1, *v*/*v*) to afford 116 fractions. Fractions 40 to 50 (19.4 g) were combined and further purified by C~18~ reversed-phase silica gel column chromatography (72 × 6.5 cm i.d.), eluted with a gradient mixture of acetone/H~2~O (40:60 to 100:0, *v*/*v*), to yield 58 subfractions, among which the subfraction 15 (1.27 g) was purified by preparative HPLC (MeCN/H~2~O, 40:60) to give compound **1** (25.0 mg). The subfraction 17 (1.50 g) was subjected to preparative HPLC (MeOH/H~2~O, 65:35) to yield compounds **2** (14.0 mg) and **4** (1.0 mg); whereas the subfraction 18 (1.36 g) was purified by preparative HPLC (MeOH/H~2~O, 69:31) to afford compounds **3** (1.3 mg) and **5** (34.3 mg). Fractions 19--20 (0.59 g) were combined and then recrystallized to afford crystals of **6** (500.0 mg) in the mixture of methanol/acetone (2:1) at room temperature.

Thaigranatin A (**1**): Colorless crystal, ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ = −134 (*c* 0.1, acetone); UV (MeCN) λ~max~ (logε) 203.6 (4.46) nm; ECD (0.34 mM, MeCN) λ~max~ (Δε) 190.9 (−17.3) nm; HR-ESIMS *m*/*z* 607.2509 \[M + Na\]^+^ (calcd. for C~32~H~40~NaO~10~, 607.2514); ^1^H (400 MHz, CDCl~3~) and ^13^C NMR spectroscopic data (100 MHz, CDCl~3~) see [Table 1](#marinedrugs-16-00434-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00434-t002){ref-type="table"}.

Thaigranatin B (**2**): Amorphous solid, ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ = −110 (*c* 0.1, acetone); UV (MeCN) λ~max~ (logε) 200.0 (4.25) nm; ECD (0.37 mM, MeCN) λ~max~ (Δε) 190.0 (−14.1), 217.6 (+2.2) nm; HR-ESIMS *m*/*z* 543.2593 \[M + H\]^+^ (calcd. for C~30~H~39~O~9~, 543.2589); ^1^H (400 MHz, CDCl~3~) and ^13^C NMR spectroscopic data (100 MHz, CDCl~3~) see [Table 1](#marinedrugs-16-00434-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00434-t002){ref-type="table"}.

Thaigranatin C (**3**): Amorphous solid, ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ = −94 (*c* 0.1, acetone); UV (MeCN) λ~max~ (logε) 203.8 (4.14), 287.2 (2.97) nm; ECD (0.34 mM, MeCN) λ~max~ (Δε) 198.6 (−9.27), 219.6 (+3.7) nm; HR-ESIMS *m*/*z* 607.2512 \[M + Na\]^+^ (calcd. for C~32~H~40~NaO~10~, 607.2514); ^1^H (400 MHz, CDCl~3~) and ^13^C NMR spectroscopic data (100 MHz, CDCl~3~) see [Table 1](#marinedrugs-16-00434-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00434-t002){ref-type="table"}.

Thaigranatin D (**4**): Amorphous solid, ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ = −130.0 (*c* 0.1, acetone); UV (MeCN) λ~max~ (logε) 201.6 (4.50) nm; ECD (0.34 mM, MeCN) λ~max~ (Δε) 198.4 (−12.0), 220.2 (+8.2) nm; HR-ESIMS *m*/*z* 585.2694 \[M + H\]^+^ (calcd. for C~32~H~41~O~10~, 585.2694); ^1^H (400 MHz, CDCl~3~) and ^13^C NMR spectroscopic data (100 MHz, CDCl~3~) see [Table 1](#marinedrugs-16-00434-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00434-t002){ref-type="table"}.

Thaigranatin E (**5**): Amorphous solid, ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ = −12.0 (*c* 0.1, acetone); UV (MeCN) λ~max~ (logε) 197.8 (4.21); ECD (0.34 mM, MeCN) λ~max~ (Δε) 195.2 (+8.7), 220.8 (−2.4), 251.8 (+0.6) nm; HR-ESIMS *m*/*z* 607.2511 \[M + Na\]^+^ (calcd. for C~32~H~40~NaO~10~, 607.2514); ^1^H (400 MHz, CDCl~3~) and ^13^C NMR spectroscopic data (100 MHz, CDCl~3~) see [Table 1](#marinedrugs-16-00434-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00434-t002){ref-type="table"}.

3.4. X-ray Crystal Data for Thaigranatin A *(**1**)* {#sec3dot4-marinedrugs-16-00434}
----------------------------------------------------

Orthorhombic, C~32~H~42~O~11~ (C~33~H~40~O~10~·H~2~O), space group *P*2(1)2(1)2(1), a = 12.1554 (1) Å, b = 14.2125 (1) Å, c = 17.2234 (2) Å, *α* = 90°, *β* = 90°, *γ* = 90°, V = 2975.49 (5) Å^3^, Z = 4, D~calcd~ = 1.323 Mg/m^3^, *μ* = 0.839 mm^−1^. Crystal size: 0.15 × 0.13 × 0.12 mm^3^. 36,359 measured reflections, 5945 \[*R*~int~ = 0.0396\] independent reflections, 400 parameters, 0 restraints, *F*(000) = 1248, *R*~1~ = 0.0398, *wR*~2~ = 0.1133 (all data), *R*~1~ = 0.0396, *wR*~2~ = 0.1131 \[*I* \> 2σ(*I*)\], and goodness-of-fit (*F*^2^) = 1.100. The absolute structural parameter Flack x is −0.02(4), and Hooft y is −0.00(3).

CCDC-1871152 (**1**) contains the [supplementary crystallographic data](#app1-marinedrugs-16-00434){ref-type="app"} for this paper (excluding structure factors). These data are provided free of charge by The Cambridge Crystallographic Data Centre.

3.5. Procedure for Structural Modification of Granatumin L *(**6**)* {#sec3dot5-marinedrugs-16-00434}
--------------------------------------------------------------------

### 3.5.1. General Procedure for the Preparation of **7** {#sec3dot5dot1-marinedrugs-16-00434}

Granatumin L (**6**) (500.0 mg) was stirred in methanol (25 mL) at room temperature for 20 min. Then 10% aqueous KOH solution was slowly added, and the mixture was stirred at room temperature for 48 h. Thin-layer chromatography (TLC) was used to monitor the products. After the reaction was completed, methanol was removed under reduced pressure. The remaining solution was neutralized with 10% HCl to pH 5--6, followed by C~18~ reversed-phase (RP~18~) HPLC to afford **7**.

**7**: White powder, Yield 96.8%; ^1^H NMR (400 MHz, CD~3~OD): *δ* 7.74 (br s, 1H), 7.47 (t, *J* = 1.6 Hz, 1H), 6.50 (d, *J* = 1.4 Hz, 1H), 5.68 (s, 1H), 5.58 (br d, *J* = 7.0 Hz, 1H), 3.93 (d, *J* = 10.0 Hz, 1H), 3.83 (d, *J* = 10.0 Hz, 1H), 3.34 (m, 1H), 2.97 (dd, *J* = 18.8, 6.0 Hz, 1H), 2.93 (d, *J* = 18.8 Hz, 1H), 2.81 (m, 1H), 2.78 (m, 1H), 2.38 (m, 1H), 2.36 (m, 1H), 2.33 (m, 1H), 2.09 (dd, *J* = 12.0, 4.0 Hz, 1H), 1.82 (qd, *J* = 12.0, 4.0 Hz, 1H), 1.68 (m, 1H), 1.54 (m, 1H), 1.48 (m, 1H), 1.10 (s, 3H), 1.06 (s, 3H), 0.70 (s, 3H); ^13^C NMR (100 MHz, CD~3~OD): *δ* 177.7, 173.8, 144.2, 143.3, 138.2, 122.7, 122.3, 110.9, 98.5, 78.8, 74.5, 69.6, 49.4, 48.3, 46.1, 43.1, 38.6, 38.1, 35.9, 34.9, 33.1, 30.8, 22.2, 20.6, 15.6, 14.8; LR-ESIMS: \[M + Na\]^+^ calcd. for C~26~H~32~NaO~8~ 495.20, found: 495.20.

### 3.5.2. General Procedure for the Preparation of **8** {#sec3dot5dot2-marinedrugs-16-00434}

TMSCHN~2~ (5.0 mL) was added to a solution of **7** (50.0 mg) in methanol (2.0 mL) at room temperature \[[@B15-marinedrugs-16-00434]\]. The solution was stirred at room temperature for 10 h and the solvent was then removed under reduced pressure. The resulting residue was dissolved in acetone and purified by RP~18~ HPLC to give **8** (44.8 mg).

**8:** White powder, Yield 89.7%; ^1^H NMR (400 MHz, CDCl~3~): *δ* 7.69 (br s, 1H), 7.40 (t, *J* = 1.6 Hz, 1H), 6.45 (br s, 1H), 5.62 (br d, *J* = 6.8 Hz, 1H), 5.57 (s, 1H), 3.90 (d, *J* = 9.6 Hz, 1H), 3.88 (dd, *J* = 10.0, 6.8 Hz, 1H), 3.68 (s, 3H), 3.39 (dd, *J* = 9.6, 2.0 Hz, 1H), 2.96 (dd, *J* = 18.8, 2.0 Hz, 1H), 2.90 (dd, *J* = 18.8, 5.6 Hz, 1H), 2.82 (br t, *J* = 8.4 Hz, 1H), 2.70 (br d, *J* = 10.4 Hz, 1H), 2.45 (s, 1H), 2.39 (dd, *J* = 16.8, 10.4 Hz, 1H), 2.32 (d, *J* = 16.8 Hz, 1H), 2.31 (m, 1H), 2.15 (br d, *J* = 12.8 Hz, 1H), 1.84 (d, *J* = 6.8 Hz, 1H), 1.77 (m, 1H), 1.65 (m, 1H), 1.61 (m, 1H), 1.45 (m, 1H), 1.10 (s, 3H), 1.05 (s, 3H), 0.66 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): *δ* 174.1, 170.4, 142.9, 141.8, 139.3, 120.7, 120.1, 109.7, 97.0, 77.1, 73.2, 68.5, 52.1, 48.0, 46.9, 45.2, 41.8, 37.6, 36.9, 34.5, 33.9, 32.0, 30.0, 21.9, 19.5, 14.8, 14.4; LR-ESIMS: \[M + H\]^+^ calcd. for C~27~H~35~O~8~ 487.23, found: 487.17.

### 3.5.3. General Procedure for the Preparation of **8a**--**8i** {#sec3dot5dot3-marinedrugs-16-00434}

Compound **8** (5.0 mg, 0.01 mmol) and various organic acid (1.5 eq.) were dissolved in dry dichloromethane (2.0 mL). Then the mixture was combined with DCC (1.5 eq.) and DMAP (1.0 eq.), and then stirred at room temperature for 3--5 h \[[@B16-marinedrugs-16-00434]\]. TLC was used to monitor the products. After the reaction was completed, the reaction solvent was evaporated. The resulting residue was dissolved in acetone or acetonitrile; whereas the insoluble matter was precipitated by centrifugation. The supernatant was purified by RP~18~ HPLC to afford the pure corresponding esterified products (**8a**--**8i**).

**8a**: white powder, yield 74.5%; ^1^H NMR (400 MHz, CDCl~3~): *δ* 8.06 (dd, *J* = 8.0 Hz, 1.2 Hz, 2H), 7.78 (br s, 1H), 7.48 (tt, *J* = 7.6 Hz, 1.2 Hz, 1H), 7.43 (t, *J* = 1.6 Hz, 1H), 7.29 (t, *J* = 8.0 Hz, 2H), 6.44 (br d, *J* = 1.2 Hz, 1H), 5.46 (s, 1H), 5.37 (br d, *J* = 7.2 Hz, 1H), 5.13 (d, *J* = 10.0 Hz, 1H), 4.00 (d, *J* = 10.0 Hz, 1H), 3.72 (s, 3H), 3.59 (dd, *J* = 10.0 Hz, 1.6 Hz, 1H), 3.11 (br d, *J* = 10.4 Hz, 1H), 3.05 (br t, *J* = 8.4 Hz, 1H), 2.72 (br d, *J* = 4.0 Hz, 2H), 2.46 (dd, *J* = 16.8 Hz, 10.8 Hz, 1H), 2.38 (dd, *J* = 16.8 Hz, 1.6 Hz, 1H), 2.24 (br s, 1H), 2.14 (dd, *J* = 12.4, 4.8 Hz, 1H), 1.65 (m, 1H), 1.81 (qd, *J* = 13.2, 4.0 Hz, 1H), 1.65 (m, 1H), 1.59 (m, 1H), 1.43 (td, *J* = 14.0, 4.0 Hz, 1H), 1.11 (s, 3H), 1.02 (s, 3H), 0.73 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): *δ* 174.0, 168.9, 166.1, 143.0, 141.8, 139.0, 133.4, 129.7, 128.9, 128.6, 120.8, 119.8, 109.8, 97.0, 76.1, 75.4, 67.9, 52.2, 48.2, 45.5, 45.0, 41.6, 37.1, 36.6, 35.0, 34.5, 31.9, 29.6, 21.5, 19.7, 15.0, 14.5; HR-ESIMS: \[M + H\]^+^ calcd. for C~34~H~39~O~9~ 591.2589, found: 591.2592.

**8b**: colorless crystal, yield 70.3%; ^1^H NMR (400 MHz, CDCl~3~): *δ* 7.89 (br d, *J* = 8.8 Hz, 2H), 7.72 (br s, 1H), 7.45 (t, *J* = 1.6 Hz, 1H), 7.40 (br d, *J* = 8.8 Hz, 2H), 6.43 (br d, *J* = 1.2 Hz, 1H), 5.42 (s, 1H), 5.36 (br d, *J* = 7.2 Hz, 1H), 5.11 (d, *J* = 10.0 Hz, 1H), 3.99 (d, *J* = 9.6 Hz, 1H), 3.72 (s, 3H), 3.58 (dd, *J* = 9.6 Hz, 1.6 Hz, 1H), 3.08 (br d, *J* = 10.4 Hz, 1H), 3.03 (br t, *J* = 8.4 Hz, 1H), 2.76 (dd, *J* = 18.8, 5.2 Hz, 1H), 2.71 (dd, *J* = 18.8, 2.0 Hz, 1H), 2.45 (dd, *J* = 16.8, 10.4 Hz, 1H), 2.37 (br d, *J* = 16.8 Hz, 1H), 2.36 (br s, 1H), 2.24 (br s, 1H), 2.15 (dd, *J* = 12.4, 4.8 Hz, 1H), 1.80 (qd, *J* = 13.2, 4.4 Hz, 1H), 1.67 (m, 1H), 1.63 (m, 1H), 1.44 (td, *J* = 14.0, 4.4 Hz, 1H), 1.10 (s, 3H), 1.01 (s, 3H), 0.70 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): *δ* 174.0, 168.9, 165.4, 143.0, 141.5, 139.2, 132.0, 131.2, 128.6, 127.9, 120.9, 119.6, 109.7, 97.0, 76.4, 75.7, 67.8, 52.2, 48.1, 45.4, 45.0, 41.6, 37.0, 36.6, 34.9, 34.4, 31.8, 29.8, 21.5, 19.7, 15.0, 14.5; HR-ESIMS: \[M + H\]^+^ calcd. for C~34~H~38~BrO~9~ 669.1694, found: 669.1699.

**8c**: colorless crystal, yield 96.4%; ^1^H NMR (400 MHz, CDCl~3~): *δ* 7.76 (br s, 1H), 7.42 (t, *J* = 1.6 Hz, 1H), 6.85 (m, 4H), 6.45 (br d, *J* = 1.2 Hz, 1H), 5.58 (s, 1H), 5.35 (br d, *J* = 6.8 Hz, 1H), 4.99 (d, *J* = 10.0 Hz, 1H), 4.67 (s, 2H), 3.92(d, *J* = 10.0 Hz, 1H), 3.66 (s, 3H), 3.49 (dd, *J* = 10.0, 1.6 Hz, 1H), 2.95 (br t, *J* = 8.4 Hz, 1H), 2.92 (dd, *J* = 18.8, 5.2 Hz, 1H), 2.86 (dd, *J* = 18.8, 1.6 Hz, 1H), 2.82 (br d, *J* = 10.4 Hz, 1H), 2.36 (m, 1H), 2.34 (m, 1H), 2.31 (m, 2H), 2.18 (m, 1H), 1.81 (qd, *J* = 13.2, 4.4 Hz, 1H), 1.66 (m, 1H), 1.61 (m, 1H), 1.46 (td, *J* = 14.4, 4.8 Hz, 1H), 1.10 (s, 3H), 1.07 (s, 3H), 0.51 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): *δ* 173.7, 170.4, 169.1, 158.8, 156.4, 153.9, 142.9, 141.8, 138.8, 120.7, 119.5, 116.0, 115.9, 115.7, 115.5, 109.8, 96.7, 77.3, 76.2, 67.8, 65.4, 52.1, 47.5, 45.1, 44.8, 41.7, 36.8, 36.2, 35.2, 34.3, 31.8, 30.3, 22.0, 19.3, 14.7, 14.5; LR-ESIMS: \[M + Na\]^+^ calcd. for C~35~H~39~FNaO~10~ 661.24, found: 661.31.

**8d**: light yellow powder, yield 85.2%; ^1^H NMR (400 MHz, CDCl~3~): *δ* 8.22 (br d, *J* = 9.2 Hz, 2H), 8.08 (br d, *J* = 9.2 Hz, 2H), 7.72 (br s, 1H), 7.45 (t, *J* = 1.6 Hz, 1H), 6.36 (br d, *J* = 1.2 Hz, 1H), 5.36 (s, 1H), 5.31 (br d, *J* = 6.8 Hz, 1H), 5.10 (d, *J* = 10.0 Hz, 1H), 4.01 (d, *J* = 10.0 Hz, 1H), 3.76 (s, 3H), 3.60 (dd, *J* = 10.0, 1.6 Hz, 1H), 3.10 (br d, *J* = 10.8 Hz, 1H), 3.06 (m, 1H), 2.73 (dd, *J* = 18.8, 5.6 Hz, 1H), 2.66 (dd, *J* = 18.8, 2.0 Hz, 1H), 2.47 (dd, *J* = 17.2, 10.8 Hz, 1H), 2.39 (br d, *J* = 17.2 Hz, 1H), 2.23 (br s, 1H), 2.16 (dd, *J* = 13.2, 4.8 Hz, 1H), 1.79 (qd, *J* = 13.2, 4.4 Hz, 1H), 1.69 (m, 1H), 1.65 (m, 1H), 1.43 (td, *J* = 10.0, 5.2 Hz, 1H), 1.12 (s, 3H), 0.98 (s, 3H), 0.74 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): *δ* 174.2, 168.8, 164.2, 150.6, 143.3, 141.4, 139.8, 134.2, 130.9, 123.8, 120.7, 119.2, 109.6, 96.9, 76.7, 76.5, 67.7, 52.3, 48.1, 45.2, 45.0, 41.6, 36.9, 36.4, 34.9, 34.3, 31.7, 29.9, 21.5, 19.7, 15.0, 14.5; HR-ESIMS: \[M + H\]^+^ calcd. for C~34~H~38~NO~11~ 636.2439, found: 636.2449.

**8e**: light yellow crystal, yield 74.0%; ^1^H NMR (400 MHz, CDCl~3~): *δ* 8.85 (t, *J* = 1.6 Hz, 1H), 8.38 (dt, *J* = 7.6, 1.2 Hz, 1H), 8.32 (dq, *J* = 8.4, 1.2 Hz, 1H), 7.68 (br s, 1H), 7.48 (t, *J* = 8.0 Hz, 1H), 7.41(t, *J* = 1.6 Hz, 1H), 6.33 (br d, *J* = 1.2 Hz, 1H), 5.32 (s, 1H), 5.29 (br d, *J* = 6.8 Hz, 1H), 5.09 (d, *J* = 10.4 Hz, 1H), 4.02 (d, *J* = 9.6 Hz, 1H), 3.80 (s, 3H), 3.60 (dd, *J* = 9.6 Hz, 2.0 Hz, 1H), 3.09 (br d, *J* = 10.4 Hz, 1H), 3.08 (overlapped, 1H), 2.70 (dd, *J* = 18.8, 5.2 Hz, 1H), 2.65 (dd, *J* = 18.8, 2.8 Hz, 1H), 2.48 (dd, *J* = 16.8, 10.4 Hz, 1H), 2.42 (br s, 1H), 2.40 (br d, *J* = 16.8 Hz, 1H), 2.22 (br s, 1H), 2.15 (dd, *J* = 12.4, 5.2 Hz, 1H), 1.79 (qd, *J* = 13.2 Hz, 4.4 Hz, 1H), 1.66 (m, 1H), 1.56 (m, 1H), 1.42 (td, *J* = 14.0, 4.4 Hz, 1H), 1.12 (s, 3H), 0.96 (s, 3H), 0.79 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): *δ* 174.0, 168.9, 164.2, 148.3, 143.1, 141.7, 139.7, 135.5, 130.6, 129.9, 127.8, 124.7, 120.5, 119.2, 109.5, 96.9, 76.9, 76.4, 67.8, 52.4, 48.0, 45.2, 44.9, 41.6, 36.9, 36.3, 35.0, 34.4, 31.8, 29.7, 21.6, 19.6, 15.1, 14.5; HR-ESIMS: \[M + H\]^+^ calcd. for C~34~H~38~NO~11~ 636.2439, found: 636.2441.

**8f**: white powder, yield 63.7%; ^1^H NMR (400 MHz, CDCl~3~): *δ* 7.98 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.73 (br s, 1H), 7.40 (t, *J* = 1.6 Hz, 1H), 7.40 (overlapped, 1H), 6.94 (d, *J* = 8.0 Hz, 1H), 6.76 (t, *J* = 7.6 Hz, 1H), 6.42 (br d, *J* = 1.2 Hz, 1H), 5.39 (s, 1H), 5.38 (br d, *J* = 6.8 Hz, 1H), 5.10 (d, *J* = 10.0 Hz, 1H), 4.0 (d, *J* = 9.6 Hz, 1H), 3.91 (s, 3H), 3.72 (s, 3H), 3.57 (dd, *J* = 9.6, 1.6 Hz, 1H), 3.06 (overlapped, 1H), 3.04 (br d, *J* = 10.8 Hz, 1H), 2.76 (dd, *J* = 18.8, 2.4 Hz, 1H), 2.71 (dd, *J* = 18.8, 5.6 Hz, 1H), 2.45 (dd, *J* = 16.8, 10.4 Hz, 1H), 2.37 (dd, *J* = 16.8, 1.6 Hz, 1H), 2.22 (br d, *J* = 2.4 Hz, 1H), 2.13 (dd, *J* = 12.4, 5.2 Hz, 1H), 1.79 (qd, *J* = 13.2, 4.4 Hz, 2H), 1.63 (m, 1H), 1.55 (m, 1H), 1.41 (td, *J* = 14.0, 4.4 Hz, 1H), 1.10 (s, 3H), 1.00 (s, 3H), 0.75 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): *δ* 174.0, 169.0, 164.9, 160.5, 142.8, 141.7, 138.6, 134.5, 132.2, 120.9, 120.3, 120.0, 117.4, 112.0, 109.9, 97.0, 76.1, 75.3, 68.1, 55.8, 52.1, 48.1, 45.5, 44.9, 41.7, 37.1, 36.5, 35.2, 34.5, 31.9, 29.6, 21.5, 19.6, 15.0, 14.6; HR-ESIMS: \[M + H\]^+^ calcd. for C~35~H~41~O~10~ 621.2694, found: 621.2709.

**8g**: pink powder, yield 55.6%; ^1^H NMR (400 MHz, CDCl~3~): *δ* 7.76 (br s, 1H), 7.42 (t, *J* = 1.6 Hz, 1H), 6.47 (br d, *J* = 1.2 Hz, 1H), 5.57 (s, 1H), 5.34 (br d, *J* = 6.8 Hz, 1H), 4.96 (d, *J* = 10.4 Hz, 1H), 3.93 (d, *J* = 9.6 Hz, 1H), 3.68 (s, 3H), 3.50 (dd, *J* = 9.6, 1.6 Hz, 1H), 2.89 (m, 1H), 2.88 (overlapped, 1H), 2.88 (overlapped, 1H), 2.87 (br d, *J* = 10.4 Hz, 1H), 2.39 (dd, *J* = 16.8, 10.4 Hz, 1H), 2.37 (m, 1H), 2.32 (dd, *J* = 16.8, 2.4 Hz, 1H), 2.30 (br s, 1H), 2.14 (dd, *J* = 12.4, 4.8 Hz, 1H), 1.96 (m, 1H), 1.92 (m, 1H), 1.77 (qd, *J* = 13.2, 4.4 Hz, 1H), 1.67 (m, 1H), 1.63 (m, 1H), 1.54 (m, 1H), 1.50 (m, 1H), 1.46 (m, 1H), 1.37 (m, 1H), 1.33 (m, 1H), 1.32 (m, 1H), 1.22 (m, 1H), 1.17 (m, 1H), 1.11 (s, 3H), 1.07 (s, 3H), 0.61 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): *δ* 175.5, 173.7, 169.9, 143.0, 141.8, 138.3, 120.7, 120.0, 109.7, 96.9, 76.7, 74.2, 67.9, 52.0, 48.0, 45.2, 45.2, 42.7, 41.6, 37.1, 36.6, 34.9, 34.5, 31.9, 30.0, 29.2, 28.4, 25.7, 25.4, 25.1, 21.7, 19.6, 14.8, 14.5; HR-ESIMS: \[M + H\]^+^ calcd. for C~34~H~45~O~9~ 597.3058, found: 597.3060.

**8h**: white powder, yield 54.2%; ^1^H NMR (400 MHz, CDCl~3~): *δ* 8.36 (d, *J* = 4.8 Hz, 1H), 7.88 (br s, 1H), 7.79 (dd, *J* = 5.2, 1.2 Hz, 1H), 7.73 (br s, 1H), 7.42 (t, *J* = 1.6 Hz, 1H), 6.37 (br d, *J* = 1.2 Hz, 1H), 5.36 (s, 1H), 5.26 (br d, *J* = 7.2 Hz, 1H), 5.05 (d, *J* = 10.0 Hz, 1H), 4.00 (d, *J* = 9.6 Hz, 1H), 3.78 (s, 3H), 3.58 (dd, *J* = 9.6, 1.6 Hz, 1H), 3.06 (br d, *J* = 10.0 Hz, 1H), 3.05 (overlapped, 1H), 2.73 (dd, *J* = 18.8, 5.6 Hz, 1H), 2.66 (br d, *J* = 18.8 Hz, 1H), 2.47 (dd, *J* = 16.8, 10.4 Hz, 1H), 2.40 (dd, *J* = 16.8, 1.6 Hz, 1H), 2.23 (br d, *J* = 2.8 Hz, 1H), 2.16 (dd, *J* = 13.0, 5.2 Hz, 1H), 1.77 (qd, *J* = 13.2, 4.0 Hz, 1H), 1.67 (m, 1H), 1.62 (m, 1H), 1.43 (td, *J* = 14.0, 4.0 Hz, 1H), 1.11 (s, 3H), 0.99 (s, 3H), 0.74 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): *δ* 174.1, 168.8, 163.5, 152.5, 150.7, 143.0, 141.7, 139.9, 138.9, 124.1, 121.7, 120.6, 119.0, 109.7, 96.9, 77.2, 76.5, 67.7, 52.3, 48.0, 45.0, 45.0, 41.6, 36.9, 36.3, 34.9, 34.3, 31.8, 29.9, 21.6, 19.6, 15.1, 14.4; HR-ESIMS: \[M + H\]^+^ calcd. for C~33~H~37~ClNO~9~ 626.2151, found: 626.2156.

**8i**: white crystal, yield 84.7%; ^1^H NMR (400 MHz, CDCl~3~): *δ* 7.76 (br s, 1H), 7.41 (t, *J* = 1.6 Hz, 1H), 6.46 (br d, *J* = 1.2 Hz, 1H), 5.56 (s, 1H), 5.32 (br d, *J* = 6.8 Hz, 1H), 4.87 (d, *J* = 10.0 Hz, 1H), 3.94 (d, *J* = 9.6 Hz, 1H), 3.69 (s, 3H), 3.50 (dd, *J* = 9.6, 1.6 Hz, 1H), 2.93 (br t, *J* = 8.4 Hz, 1H), 2.89 (dd, *J* = 18.8, 3.2 Hz, 1H), 2.85 (overlapped, 1H), 2.85 (br d, *J* = 10.4 Hz, 1H), 2.40 (dd, *J* = 16.8, 10.8 Hz, 1H), 2.36 (overlapped, 1H), 2.33 (dd, *J* = 16.8, 3.2 Hz, 1H), 2.31 (overlapped, 1H), 2.29 (br s, 1H), 2.15 (dd, *J* = 12.4, 5.2 Hz, 1H), 1.79 (qd, *J* = 13.2, 4.4 Hz, 1H), 1.63 (m, 1H), 1.56 (m, 1H), 1.45 (td, *J* = 13.2, 4.4 Hz, 1H), 1.25 (m, 2H), 1.24 (m, 2H), 1.22 (m, 2H), 1.20 (m, 2H), 1.19 (m, 2H), 1.10 (s, 3H), 1.07 (s, 3H), 0.83(t, *J* = 7.2 Hz, 3H), 0.63 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): *δ* 173.8, 173.8, 169.9, 142.9, 141.8, 138.4, 120.8, 120.0, 109.8, 96.8, 76.9, 75.0, 68.0, 52.0, 47.8, 45.1, 45.0, 41.6, 36.9, 36.2, 35.1, 34.5, 33.9, 31.9, 31.6, 30.1, 29.1, 28.9, 24.7, 22.6, 21.8, 19.4, 14.8, 14.5, 14.1; HR-ESIMS: \[M + H\]^+^ calcd. for C~35~H~49~O~9~ 613.3371, found: 613.3380.

### 3.5.4. General Procedure for the Preparation of **9** {#sec3dot5dot4-marinedrugs-16-00434}

Compound **8** (50.0 mg) was dissolved in DMSO (2.0 mL) at room temperature. Then IBX (42.0 mg) was added \[[@B17-marinedrugs-16-00434]\]. The mixture was stirred at room temperature for 7.5 h. The solvent was then removed by lyophilization. The resulting residue was dissolved in acetone and purified by RP~18~ HPLC to give **9** (49.2 mg).

**9**: White powder, Yield 98.4%; ^1^H NMR (400 MHz, CDCl~3~): *δ* 7.64 (br s, 1H), 7.39 (t, *J* = 1.6 Hz, 1H), 6.42 (br d, *J* = 1.2 Hz, 1H), 5.77 (dt, *J* = 7.2, 2.0 Hz, 1H), 5.36 (s, 1H), 4.02 (d, *J* = 9.6 Hz, 1H), 3.69 (s, 3H), 3.55 (dd, *J* = 9.6, 1.6 Hz, 1H), 3.01 (br d, *J* = 7.2 Hz, 1H), 2.92 (s, 1H), 2.91 (d, *J* = 2.8 Hz, 1H), 2.74 (s, 1H), 2.58 (br d, *J* = 10.4 Hz, 1H), 2.51 (dd, *J* = 16.0, 10.4 Hz, 1H), 2.43 (br d, *J* = 16.0 Hz, 1H), 2.33 (overlapped, 1H), 2.30 (m, 1H), 1.72 (m, 1H), 1.67 (m, 1H), 1.63 (m, 1H), 1.45 (m, 1H), 1.20 (s, 3H), 1.11 (s, 3H), 0.79 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): *δ* 207.2, 173.2, 169.6, 143.0, 141.8, 138.4, 120.5, 119.1, 109.6, 97.8, 76.6, 66.1, 57.0, 52.4, 48.6, 46.4, 44.9, 42.2, 36.9, 36.8, 34.3, 31.7, 29.6, 21.8, 19.1, 14.5, 11.4; LR-ESIMS: \[M + H\]^+^ calcd. for C~27~H~33~O~8~ 485.21, found: 485.14.

### 3.5.5. General Procedure for the Preparation of **9a** and **9b** {#sec3dot5dot5-marinedrugs-16-00434}

Compound **9** (5.0 mg, 0.01 mmol) and oxyamine (4 eq.) in ethanol (2 mL) were added with pyridine (4 eq.), and then stirred at room temperature for 48 h \[[@B18-marinedrugs-16-00434]\]. TLC was used to monitor the products. After the reaction was completed, the reaction solvent was precipitated by centrifugation. The resulting supernatant was purified by RP~18~ HPLC to give the pure corresponding derivatives, **9a** and **9b**.

**9a**: White powder, Yield 51.0%; ^1^H NMR (400 MHz, CDCl~3~): *δ* 7.65 (br s, 1H), 7.39 (t, *J* = 1.6 Hz, 1H), 6.42 (br d, *J* = 1.2 Hz, 1H), 6.07 (br d, *J* = 6.4 Hz, 1H), 5.40 (s, 1H), 3.97 (d, *J* = 9.2 Hz, 1H), 3.70 (s, 3H), 3.52 (overlapped, 1H), 3.52 (dd, *J* = 9.2, 1.2 Hz, 1H), 2.97 (br d, *J* = 18.8 Hz, 1H), 2.90 (dd, *J* = 18.8, 6.0 Hz, 1H), 2.54 (br d, *J* = 10.8 Hz, 1H), 2.48 (dd, *J* = 16.0, 10.8 Hz, 1H), 2.38 (br d, *J* = 16.0 Hz, 1H), 2.31 (br d, *J* = 2.8 Hz, 1H), 2.18 (dd, *J* = 12.0, 5.6 Hz, 1H), 1.71 (m, 1H), 1.64 (m, 1H), 1.59 (m, 1H), 1.42 (m, 1H), 1.13 (s, 3H), 1.09 (s, 3H), 0.86 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): *δ* 173.6, 170.4, 161.0, 143.0, 141.8, 136.6, 120.6, 119.9, 109.7, 97.2, 76.9, 68.4, 52.3, 47.9, 45.4, 44.8, 42.1, 39.5, 38.6, 36.8, 34.4, 32.0, 29.8, 21.8, 19.2, 14.7, 13.0; LR-ESIMS: \[M + H\]^+^ calcd. for C~27~H~34~NO~8~ 500.22, found: 500.16.

**9b**: White powder, Yield 60.0%; ^1^H NMR (400 MHz, CDCl~3~): δ 7.67 (br s, 1H), 7.40 (t, *J* = 1.6 Hz, 1H), 6.43 (br d, *J* = 1.2 Hz, 1H), 5.97 (dt, *J* = 6.8, 2.0 Hz, 1H), 5.42 (s, 1H), 3.97 (d, *J* = 9.2 Hz, 1H), 3.86 (s, 3H), 3.69 (s, 3H), 3.51 (dd, *J* = 9.2 Hz, 1.6 Hz, 1H), 3.43 (br d, *J* = 6.8 Hz, 1H), 2.97 (dd, *J* = 18.8, 1.6 Hz, 1H), 2.89 (dd, *J* = 18.8, 6.4 Hz, 1H), 2.53 (br d, *J* = 10.8 Hz, 1H), 2.48 (dd, *J* = 15.6, 10.8 Hz, 1H), 2.41 (s, 1H), 2.37 (br d, *J* = 15.6 Hz, 1H), 2.31 (m, 1H), 2.19 (dd, *J* = 12.4, 5.2 Hz, 1H), 1.71 (qd, *J* = 13.2, 4.0 Hz, 1H), 1.66 (m, 1H), 1.58 (m, 1H), 1.43 (td, *J* = 14.0, 4.8 Hz, 1H), 1.12 (s, 3H), 1.09 (s, 3H), 0.86 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): *δ* 173.5, 170.0, 159.5, 142.9, 141.8, 136.4, 120.6, 120.2, 109.6, 97.2, 76.8, 68.6, 61.8, 52.2, 47.9, 46.0, 44.9, 42.1, 39.6, 38.6, 36.8, 34.4, 32.1, 29.8, 21.8, 19.2, 14.6, 13.0; LR-ESIMS: \[M + Na\]^+^ calcd. for C~28~H~35~NNaO~8~ 536.23, found: 536.30.

### 3.5.6. General Procedure for the Preparation of **10** {#sec3dot5dot6-marinedrugs-16-00434}

Compound **7** (50.0 mg) was dissolved in DMSO (2.0 mL) at room temperature. Then IBX (42.0 mg) was added \[[@B17-marinedrugs-16-00434]\]. Then the mixture was stirred for 7.5 h. TLC was used to monitor the products. Then the solvent was removed by lyophilization. The resulting residue was dissolved in acetone and purified by RP~18~ HPLC to afford **10** (49.4 mg).

**10**: White powder, Yield 98.8%; ^1^H NMR (400 MHz, CD~3~COCD~3~): *δ* 7.70 (br s, 1H), 7.54 (br s, 1H), 6.51 (br s, 1H), 5.69 (br d, *J* = 5.2 Hz, 1H), 5.35 (s, 1H), 4.14 (d, *J* = 9.6 Hz, 1H), 3.45 (d, *J* = 9.6 Hz, 1H), 3.00 (dd, *J* = 18.4, 6.4 Hz, 1H), 2.95 (d, *J* = 6.4 Hz, 1H), 2.82 (br d, *J* = 18.4 Hz, 1H), 2.65 (m, 1H), 2.60 (m, 1H), 2.59 (overlapped, 1H), 2.42 (br d, *J* = 6.4 Hz, 1H), 2.35 (dd, *J* = 12.0, 4.8 Hz, 1H), 1.78 (m, 1H), 1.71 (m, 1H), 1.55 (m, 1H), 1.52 (m, 1H), 1.26 (s, 3H), 1.14 (s, 3H), 0.79 (s, 3H); ^13^C NMR (100 MHz, CD~3~COCD~3~): *δ* 209.4, 175.6, 169.5, 144.1, 142.8, 139.7, 122.1, 120.1, 110.8, 98.4, 77.1, 66.3, 57.9, 49.5, 47.2, 45.6, 43.0, 37.7, 37.4, 35.1, 31.7, 30.4, 22.2, 19.8, 14.9, 12.0; LR-ESIMS: \[M + H\]^+^ calcd. for C~26~H~31~O~8~ 471.20, found: 471.14.

### 3.5.7. General Procedure for the Preparation of **10a**--**10c** {#sec3dot5dot7-marinedrugs-16-00434}

Compound **10** (5.0 mg, 0.01 mmol) and oxyamine (4 eq.) in ethanol (2 mL) were added with pyridine (4 eq.), and then stirred at room temperature for 48 h \[[@B18-marinedrugs-16-00434]\]. TLC was used to monitor the products. After the reaction was completed, the solvent was precipitated by centrifugation. The supernatant was purified by RP~18~ HPLC to give the pure corresponding derivatives (**10a**--**10c**).

**10a**: white powder, yield 65.8%; ^1^H NMR (400 MHz, CD~3~COCD~3~): *δ* 7.73 (br s, 1H), 7.54 (t, *J* = 1.6 Hz, 1H), 6.52 (d, *J* = 1.2 Hz, 1H), 6.02 (dt, *J* = 6.8 Hz, 1H), 5.39 (s, 1H), 4.05 (d, *J* = 9.2 Hz, 1H), 3.52 (br d, *J* = 6.8 Hz, 1H), 3.37 (dd, *J* = 9.2, 1.6 Hz, 1H), 2.95 (dd, *J* = 18.4, 6.4 Hz, 1H), 2.83 (br d, *J* = 18.4 Hz, 1H), 2.58 (br t, *J* = 7.2 Hz, 1H), 2.56 (dd, *J* = 20.8, 8.2 Hz, 1H), 2.51 (dd, *J* = 20.8, 7.2 Hz, 1H), 2.37 (m, 1H), 2.22 (m, 1H), 1.74 (m, 1H), 1.71 (m, 1H), 1.51 (m, 1H), 1.48 (m, 1H), 1.19 (s, 3H), 1.13 (s, 3H), 0.89 (s, 3H); ^13^C NMR (100 MHz, CD~3~COCD~3~): *δ* 175.7, 169.5, 161.5, 144.0, 142.8, 137.6, 122.2, 120.9, 110.8, 97.8, 77.0, 69.0, 49.0, 46.4, 45.6, 42.8, 40.2, 39.4, 37.4, 35.3, 32.0, 30.5, 22.2, 19.9, 15.1, 13.7; LR-ESIMS: \[M + H\]^+^ calcd. for C~26~H~32~NO~8~ 486.21, found: 486.16.

**10b**: transparent crystal, yield 74.3%; ^1^H NMR (400 MHz, CD~3~COCD~3~): *δ* 7.73 (br s, 1H), 7.54 (t, *J* = 1.6 Hz, 1H), 6.53 (d, *J* = 1.6 Hz, 1H), 5.89 (dt, *J* = 6.4, 2.0 Hz, 1H), 5.38 (br s, 1H), 4.06 (d, *J* = 9.2 Hz, 1H), 3.78 (s, 3H), 3.43 (br d, *J* = 6.4 Hz, 1H), 3.37 (d, *J* = 8.8 Hz, 1H), 2.95 (dd, *J* = 18.4, 6.4 Hz, 1H), 2.78 (d, *J* = 18.4 Hz, 1H), 2.57 (br t, *J* = 7.2 Hz, 1H), 2.55 (d, *J* = 16.4 Hz, 1H), 2.53 (dd, *J* = 16.4, 7.2 Hz, 1H), 2.37 (br d, *J* = 6.4 Hz, 1H), 2.22 (m, 1H), 1.75 (m, 1H), 1.71 (m, 1H), 1.52 (m, 1H), 1.49 (m, 1H), 1.18 (s, 3H), 1.13 (s, 3H), 0.90 (s, 3H); ^13^C NMR (100 MHz, CD~3~COCD~3~): *δ* 175.7, 169.6, 162.4, 144.0, 142.8, 138.0, 122.2, 120.7, 110.8, 97.6, 77.1, 68.8, 61.7, 48.9, 46.7, 45.6, 42.8, 40.2, 39.4, 37.4, 35.2, 31.9, 30.6, 22.2, 19.8, 15.0, 13.6; LR-ESIMS: \[M + Na\]^+^ calcd. for C~27~H~34~NO~8~ 500.22, found: 500.17.

**10c**: transparent oil, yield 23.6%; ^1^H NMR (400 MHz, CD~3~COCD~3~): *δ* 7.75 (br s, 1H), 7.55 (t, *J* = 1.6 Hz, 1H), 7.41 (m, 1H), 7.39 (overlapped, 1H), 7.37 (m, 1H), 7.28 (m, 1H), 6.55 (d, *J* = 1.6 Hz, 1H), 5.97 (dt, *J* = 4.8, 2.0 Hz, 1H), 5.43 (s, 1H), 5.05 (dd, *J* = 12.0, 4.0 Hz, 2H), 4.07 (d, *J* = 9.2 Hz, 1H), 3.47 (d, *J* = 6.8 Hz, 1H), 3.37 (d, *J* = 8.8 Hz, 1H), 2.98 (dd, *J* = 18.4, 6.4 Hz, 1H), 2.80 (d, *J* = 18.4 Hz, 1H), 2.62 (d, *J* = 8.6 Hz, 1H), 2.58 (d, *J* = 5.8 Hz, 1H), 2.53 (d, *J* = 13.8 Hz, 1H), 2.39 (d, *J* = 6.4 Hz, 1H), 2.23 (t, *J* = 9.6 Hz, 1H), 1.76 (m, 1H), 1.73 (m, 1H), 1.53 (m, 1H), 1.50 (m, 1H), 1.18 (s, 3H), 1.15 (s, 3H), 0.90 (s, 3H); ^13^C NMR (100 MHz, CD~3~COCD~3~): *δ* 175.7, 169.6, 162.8, 144.1, 142.8, 139.0, 138.3, 129.2, 129.0, 128.4, 122.2, 120.5, 110.8, 97.7, 77.1, 76.4, 68.9, 49.0, 46.9, 45.6, 42.8, 40.2, 39.6, 37.5, 35.3, 32.0, 30.6, 22.2, 19.8, 15.0, 13.6; LR-ESIMS: \[M + H\]^+^ calcd. for C~33~H~38~NO~8~ 576.25, found: 576.18.

3.6. Antiviral Bioassay {#sec3dot6-marinedrugs-16-00434}
-----------------------

Antiviral activities of **6**, **7**--**10**, **8a**--**8i**, **9a**--**9b**, and **10a**--**10c** against HIV-1 and IAV were performed according to references \[[@B14-marinedrugs-16-00434],[@B19-marinedrugs-16-00434]\]. 293T cells (2 × 10^5^) were co-transfected with 0.6 μg of pNL-Luv-E^−^-Vpu^−^ and 0.4 μg of pHIT/G. After 48 h, the VSV-G pseudo-typed viral supernatant was harvested by filtration through a 0.45 μm filter, and the concentration of viral capsid protein was determined by p24 antigen capture ELISA (Biomerieux). SupT1 cells were exposed to VSV-G pseudo-typed virus (MOI = 1) at 37 °C for 48 h in the absence or presence of compounds at different concentrations. The inhibition rate was determined by using a firefly luciferase assay system (Promega, Beijing). Efavirenz was used as the positive control for HIV-1; whereas ribavirion was used as the positive control for IAV.

4. Conclusions {#sec4-marinedrugs-16-00434}
==============

In conclusion, five new limonoids named thaigranatins A--E (**1**--**5**), containing a C~1~--*O*--C~29~ moiety, were isolated from seeds of the Thai *Xylocarpus granatum*, collected at the mangrove swamp of Trang Province, together with the known one, granatumin L (**6**). The structures of these limonoids, including absolute configurations of **1**, **2**, and **6** were established by HR-ESIMS, extensive NMR investigations, single-crystal X-ray diffraction analysis (Cu Kα radiation), and comparison of experimental ECD spectra. The structural modification of **6** via hydrolysis, esterification, and oximization, afforded 18 derivatives, *viz.* **7**--**10**, **8a**--**8i**, **9a**--**9b**, and **10a**--**10c**. The derivative **8i** exhibited marked inhibitory activity against HIV-1 with an IC~50~ value of 15.98 ± 6.87 μM and a CC~50~ value greater than 100.0 μM; whereas **10b** showed significant inhibitory activity against IAV with an IC~50~ value of 14.02 ± 3.54 μM and a CC~50~ value greater than 100.0 μM. These results demonstrate that the mangrove *X.* *granatum* continues to be an abundant resource to produce new antiviral limonoids. In-depth structural modification and structure-activity relationship studies of the limonoid skeleton of **6** will be proceeded by us for the discovery of antiviral drug leads.

We thank Patchara Pedpradab (Rajamangala University of Technology Srivijaya, Trang Province, Thailand) for providing the plant materials in this work.

The following are available online at <http://www.mdpi.com/1660-3397/16/11/434/s1>. Copies of HR-ESIMS, 1D and 2D NMR spectra of compounds **1**--**5**; and copies of LR/HR-ESIMS and 1D NMR spectra of compounds **7**, **8**, **9**, **10**, **8a**--**8i**, **9a**, **9b**, and **10a**--**10c**.
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![Structures of compounds **1**--**6**.](marinedrugs-16-00434-g001){#marinedrugs-16-00434-f001}

![(**a**) Selected ^1^H--^1^H COSY and HMBC correlations for **1**; (**b**) Diagnostic NOE interactions for **1** (measured in CDCl~3~).](marinedrugs-16-00434-g002){#marinedrugs-16-00434-f002}

![ORTEP illustration of the X-ray structure of **1**. Ellipsoids are given at the 10% probability level.](marinedrugs-16-00434-g003){#marinedrugs-16-00434-f003}

![Comparison of the experimental ECD spectra of **1**, **2**, and the known compound, granatumin L (**6**), containing a Δ^8,30^ double bond (recorded at the concentration of 200 μg mL^−1^ in MeCN).](marinedrugs-16-00434-g004){#marinedrugs-16-00434-f004}

![(**a**) Selected ^1^H--^1^H COSY and HMBC correlations for **3**; (**b**) Diagnostic NOE interactions for **3** (measured in CDCl~3~).](marinedrugs-16-00434-g005){#marinedrugs-16-00434-f005}

![Summary of the structural modification approaches undertaken in this work. Reagent and conditions: (i) 10% KOH, CH~3~OH, r.t., 30.0 h; (ii) TMSCHN~2~, CH~3~OH, r.t., 2.0 h; (iii) organic acids, DMAP, DCC, CH~2~Cl~2~, r.t., 3--12 h; (iv) IBX (2-iodoxybenzoic acid), DMSO, r.t., 7.5 h; (v) TMSCHN~2~, CH~3~OH, r.t., 4.0 h; (vi) IBX, DMSO, r.t., 7.5 h; (vii) (viii) RONH~2~, Pyridine, CH~3~CH~2~OH, r.t., 24--36 h.](marinedrugs-16-00434-sch001){#marinedrugs-16-00434-sch001}

marinedrugs-16-00434-t001_Table 1

###### 

^1^H (400 MHz) NMR spectroscopic data of compounds **1**--**5** in CDCl~3~ (*δ* in ppm, *J* in Hz).

  Position        1               2                      3                     4                     5
  --------------- --------------- ---------------------- --------------------- --------------------- ----------------------
  2               3.00 t (8.4)    2.95 t (8.4)           2.77 dd (10.8, 2.4)   2.57 m                2.78 dd (10.4, 1.6)
  3               4.71 d (10.0)   4.84 d (10.0)          5.14 d (10.8)         4.82 d (10.4)         5.27 d (10.8)
  5               2.93 s          2.84 d (10.0)          2.98 d (10.8)         2.92 br s             2.64 ^a^
  6a              4.56 s          2.35 m                 2.42 dd (16.8, 2.0)   4.59 s                2.35 m
  6b              2.35 m          2.42 dd (16.8, 10.8)   2.64 ^a^                                    
  9               2.24 m          2.15 dd (12.2, 5.2)    2.65 br s             2.46 m                
  11*α*           1.76 m          1.62 ^a^               1.73 m                1.73 m                1.97 m
  11*β*           1.76 m          1.77 m                 1.79 m                1.73 m                2.23 m
  12*α*           1.52 m          1.45 m                 1.11 m                1.20 m                1.51 m
  12*β*           1.71 m          1.62 ^a^               1.62 m                1.62 m                1.51 m
  14              2.31 br s       2.30 br s                                                          2.52 mdd (11.6, 5.2)
  15*α*           2.80 d (21.6)   2.84 d (21.6)          3.41 dd (21.2, 3.2)   3.25 dt (21.6, 2.8)   2.69 dd (16.0, 3.2)
  15*β*           2.84 d (21.6)   2.91 d (21.6)          3.59 dd (21.2, 1.6)   3.44 d (21.6)         2.18 dd (16.0, 3.2)
  17              5.42 s          5.55 s                 5.41 s                5.33 s                4.90 s
  18              0.98 s          1.09 s                 1.08 s                0.98 s                0.78 s
  19              1.40 s          1.07 s                 1.13 s                1.38 s                1.11 s
  21              7.50 br s       7.74 br s              7.53 br s             7.44 br s             7.44 br s
  22              6.38 br s       6.45 br s              6.46 br s             6.38 br s             6.41 br s
  23              7.44 br s       7.41 br s              7.42 br s             7.42 br s             7.42 br s
  28              0.77 s          0.63 s                 0.56 s                0.71 s                0.70 s
  H~*pro-S*~-29   4.60 d (8.8)    3.93 d (9.6)           3.92 d (9.6)          4.59 d (8.8)          3.80 d (10.0)
  H~*pro-R*~-29   3.45 d (8.8)    3.48 dd (9.6, 1.6)     3.51 dd (9.6, 1.6)    3.42 (8.8, 1.6)       3.69 (10.0)
  30*β*           5.28 d (6.8)    5.31 d (6.8)           4.51 d (2.4)          2.24 m                3.94 br s
  30*α*           2.24 m                                                                             
  31              3.76 s          3.69 s                 3.70 s                3.84 s                3.72 s
                  3-Acyl          3-Acyl                 3-Acyl                3-Acyl                3-Acyl
  33                              2.37 m                                                             
  2.37 m                                                                                             
  34              6.83 q (7.2)    1.09 t (7.2)           6.99 q (7.2)          6.92 q (7.2)          6.89 q (7.2)
  35              1.67 d (7.2)                           1.80 dd (7.2, 1.2)    1.80 dd (7.2, 0.8)    1.86 d (7.2)
  36              1.79 s                                 1.87 s                1.86 s                1.88 s

^a^ Overlapped signals assigned by ^1^H--^1^H COSY, HSQC, and HMBC spectra without designating multiplicity.
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###### 

^13^C (100 MHz) NMR spectroscopic data of compounds **1**--**5** in CDCl~3~ (*δ* in ppm).

  Position   1            2            3            4            5
  ---------- ------------ ------------ ------------ ------------ ------------
  1          96.9 qC      96.9 qC      97.4 qC      97.1 qC      97.4 qC
  2          45.3 CH      45.1 CH      48.2 CH      43.6 CH      46.2 CH
  3          76.2 CH      75.2 CH      75.2 CH      78.5 CH      74.8 CH
  4          36.6 qC      36.2 qC      37.1 qC      36.6 qC      36.8 qC
  5          39.6 CH      35.0 CH      34.5 CH      39.3 CH      40.6 CH
  6          72.5 CH      31.9 CH~2~   32.1 CH~2~   73.1 CH      31.9 CH~2~
  7          176.1 qC     173.9 qC     174.2 qC     175.8 qC     174.3 qC
  8          138.3 qC     138.4 qC     131.3 qC     130.6 qC     127.1 qC
  9          48.9 CH      47.8 CH      38.7 CH      43.9 CH      139.2 qC
  10         42.1 qC      41.6 qC      45.1 qC      44.7 qC      43.6 qC
  11         20.4 CH~2~   19.4 CH~2~   17.7 CH~2~   18.2 CH~2~   21.1 CH~2~
  12         34.6 CH~2~   34.5 CH~2~   29.4 CH~2~   30.3 CH~2~   29.4 CH~2~
  13         36.7 qC      36.9 qC      38.2 qC      37.8 qC      35.3 qC
  14         44.8 CH      45.0 CH      134.3 qC     129.0 qC     36.8 CH
  15         29.6 CH~2~   30.1 CH~2~   32.3 CH~2~   33.1 CH~2~   32.2 CH~2~
  16         169.3 qC     170.1 qC     169.5 qC     169.8 qC     172.7 qC
  17         76.6 CH      77.0 CH      80.7 CH      81.6 CH      81.3 CH
  18         21.2 CH~3~   21.9 CH~3~   17.4 CH~3~   18.0 CH~3~   20.2 CH~3~
  19         14.9 CH~3~   14.4 CH~3~   14.2 CH~3~   15.1 CH~3~   14.3 CH~3~
  20         121.5 qC     120.8 qC     120.7 qC     121.1 qC     121.2 qC
  21         140.3 CH     141.8 CH     141.6 CH     140.9 CH     140.4 CH
  22         109.3 CH     109.7 CH     109.9 CH     109.8 CH     109.7 CH
  23         143.1 CH     143.0 CH     142.9 CH     143.1 CH     143.2 CH
  28         15.8 CH~3~   14.8 CH~3~   15.6 CH~3~   16.4 CH~3~   18.2 CH~3~
  29         70.1 CH~2~   68.0CH~2~    67.6 CH~2~   70.0 CH~2~   68.6 CH~2~
  30         120.2 CH     119.9 CH     66.3 CH      26.4 CH~2~   66.1 CH
  31         53.2 CH~3~   52.1 CH~3~   52.1 CH~3~   53.1 CH~3~   52.0 CH~3~
             3-Acyl       3-Acyl       3-Acyl       3-Acyl       3-Acyl
  32         167.2 qC     174.5 qC     167.6 qC     167.5 qC     167.6 qC
  33         127.8 qC     27.2 CH~2~   128.8 qC     128.9 qC     128.4 qC
  34         138.7 CH     8.8 CH~3~    139.6 CH     138.7 CH     139.2 CH
  35         14.6 CH~3~                14.6 CH~3~   14.6 CH~3~   14.8 CH~3~
  36         11.7 CH~3~                12.3 CH~3~   12.2 CH~3~   12.4 CH~3~

marinedrugs-16-00434-t003_Table 3

###### 

Inhibitory activities of natural limonoid **6** and its modified derivatives against HIV-1.

  cpd No.   Inhibition Rate (20.0 μM) (%)   IC~50~ Value (μM)   CC~50~ Value (μM)   cpd No.   Inhibition Rate (20.0 μM) (%)   IC~50~ Value (μM)   CC~50~ Value (μM)
  --------- ------------------------------- ------------------- ------------------- --------- ------------------------------- ------------------- -------------------
  6         67.10 ± 3.04                    19.23 ± 0.12        \> 100              8f        NA                              NT                  NT
  7         NA                              NT                  NT                  8g        50.84 ± 6.96                    21.98 ± 4.65        86.76 ± 4.76
  8         NA                              NT                  NT                  8h        NA                              NT                  NT
  9         NA                              NT                  NT                  8i        99.95 ± 0.01                    15.98 ± 6.87        \> 100
  10        NA                              NT                  NT                  9a        NA                              NT                  NT
  8a        NA                              NT                  NT                  9b        NA                              NT                  NT
  8b        39.87 ± 2.83                    NT                  NT                  10a       NA                              NT                  NT
  8c        45.47 ± 6.84                    NT                  NT                  10b       NA                              NT                  NT
  8d        35.63 ± 8.85                    NT                  NT                  10c       NA                              NT                  NT
  8e        10.58 ± 3.55                    NT                  NT                  EFV       88.78 ± 4.54 (4 nM)             NT                  NT

cpd: compound; NA: No activity; NT = Not tested.
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###### 

Inhibitory activities of natural limonoid **6** and its modified derivatives against IAV.

  cpd No.   Inhibition Rate (20.0 μM) (%)   IC~50~ Value (μM)   CC~50~ Value (μM)   cpd No.     Inhibition Rate (20.0 μM) (%)   IC~50~ Value (μM)   CC~50~ Value (μM)
  --------- ------------------------------- ------------------- ------------------- ----------- ------------------------------- ------------------- -------------------
  7         38.25 ± 9.67                    NT                  NT                  8e          43.42 ± 1.79                    NT                  NT
  8         NA                              NT                  NT                  8f          44.94 ± 9.73                    NT                  NT
  9         NA                              NT                  NT                  8h          48.15 ± 1.64                    NT                  NT
  10        NA                              NT                  NT                  9a          44.72 ± 1.43                    NT                  NT
  8a        23.46 ± 2.42                    NT                  NT                  10a         NA                              NT                  NT
  8b        54.65 ± 1.43                    17.93 ± 4.76        85.90 ± 4.65        10b         63.40 ± 7.43                    14.02 ± 3.54        \> 100
  8c        68.61 ± 0.99                    15.87 ± 6.54        77.98 ± 4.65        10c         NA                              NT                  NT
  8d        51.41 ± 1.54                    22.78 ± 1.86        87.65 ± 4.76        ribavirin   87.54 ± 2.86 (60 μM)            NT                  NT

cpd: compound; NA: No activity; NT = Not tested.

[^1]: These authors contributed equally.
